Neue Studien: Psoriasis im JDDGhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/?d=1Neue Studien: Psoriasis im JDDGdeUneinheitliche Standards beim Tuberkulose‐Screening und der präventiven Tuberkulosetherapie vor Beginn einer systemischen Psoriasistherapiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/uneinheitliche-standards-beim-tuberkulose%E2%80%90screening-und-der-pr%C3%A4ventiven-tuberkulosetherapie-vor-beginn-einer-systemischen-psoriasistherapie-r637/No abstract supplied.

Weiterlesen

]]>637Mon, 29 Jun 2026 08:21:11 +0000PeakPASI as a marker of maximum psoriasis severity: a single-center, cross-sectional retrospective and questionnaire-based study.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/peakpasi-as-a-marker-of-maximum-psoriasis-severity-a-single-center-cross-sectional-retrospective-and-questionnaire-based-study-r636/BackgroundThe Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long-term disease burden. To assess whether the highest-ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and comorbidities.

Patients and methods

A cross-sectional analysis of 308 psoriasis patients from a German university hospital was conducted. Data on PASI, PeakPASI, therapies, and comorbidities were obtained from self-report and medical records. Group comparisons used non-parametric tests; Poisson regression assessed PeakPASI as a predictor of systemic therapy use and comorbidity burden.

Results

Median PeakPASI (11.4 [IQR 5.9-17.0]) exceeded current PASI (2.0 [IQR 1.0-5.1]). PeakPASI ≥ 10 was associated with more systemic therapies (p < 0.001), phototherapy (p < 0.001), smoking (p = 0.021), and diabetes (p = 0.020). PeakPASI correlated with number of systemic (ρ = 0.296), topical therapies (ρ = 0.367), and hospital visits (ρ = 0.186). It significantly predicted systemic therapy use (β = 0.355, p < 0.001), but not comorbidity burden.

Conclusions

PeakPASI may complement current measures by reflecting historical severity and informing treatment. While not a cumulative burden marker, it may prevent underestimation of long-term disease impact. Prospective validation is warranted.

Weiterlesen

]]>636Mon, 29 Jun 2026 08:21:11 +0000S1 Guideline: Therapy of generalized pustular psoriasis.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s1-guideline-therapy-of-generalized-pustular-psoriasis-r635/Weiterlesen

]]>635Mon, 29 Jun 2026 08:21:11 +0000Severe generalized pustular psoriasis complicated with staphylococcal toxic shock syndrome treated with spesolimab and antibiotics.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/severe-generalized-pustular-psoriasis-complicated-with-staphylococcal-toxic-shock-syndrome-treated-with-spesolimab-and-antibiotics-r634/No abstract supplied.

Weiterlesen

]]>634Mon, 29 Jun 2026 08:21:11 +0000Trust in skincare and topical therapies in atopic dermatitis or psoriasis: a German cross-sectional study.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/trust-in-skincare-and-topical-therapies-in-atopic-dermatitis-or-psoriasis-a-german-cross-sectional-study-r633/Background and objectivesTrust in therapy impacts adherence and satisfaction in chronic inflammatory skin diseases, including atopic dermatitis (AD) and psoriasis (PSO). This study assessed and compared trust in skincare and topical therapies and explored influencing factors among AD and PSO patients.

Patients and methods

Cross-sectional surveys of AD or PSO patients were conducted at two dermatological university centers in Germany. Group differences were analyzed using Mann-Whitney U and Kruskal-Wallis tests; associations between trust (6-point Likert scale: 1 = very high, 6 = none) and demographics, disease severity, pruritus, pain, and quality of life (QoL) using Spearman correlations. All analyses were exploratory.

Results

Among 253 AD or PSO patients (median age 53.0 years, interquartile range 36.0-63.0; 43.9% female) median trust in skin care and topical therapies was moderate. AD patients reported significantly higher trust than PSO patients. In AD, trust in skin care correlated with pruritus intensity (p < 0.001), pain intensity (p < 0.05), and QoL (p < 0.001); trust in topical therapy correlated with QoL (p < 0.01). No significant correlations were observed in PSO.

Conclusions

Trust levels were higher in AD than in PSO but tended to decline with increasing disease burden and poorer QoL. Enhancing patient education and shared decision-making may help improve trust and adherence.

Weiterlesen

]]>633Mon, 29 Jun 2026 08:21:11 +0000Unterschiedliche anatomische Spezifitäten des residualen PASI bei Biologikatherapien der Psoriasishttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/unterschiedliche-anatomische-spezifit%C3%A4ten-des-residualen-pasi-bei-biologikatherapien-der-psoriasis-r622/No abstract supplied.

Weiterlesen

]]>622Mon, 25 May 2026 08:01:34 +0000Dermal lipomatous metaplasia in chronic plaque psoriasis: A clinicopathological case report.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/dermal-lipomatous-metaplasia-in-chronic-plaque-psoriasis-a-clinicopathological-case-report-r621/No abstract supplied.

Weiterlesen

]]>621Mon, 25 May 2026 08:01:34 +0000Dupilumab-Induced Psoriasis in a Patient with Bullous Pemphigoid.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/dupilumab-induced-psoriasis-in-a-patient-with-bullous-pemphigoid-r620/No abstract supplied.

Weiterlesen

]]>620Thu, 14 May 2026 18:05:27 +0000Safety of biologic therapy in psoriasis patients with a previous malignancy: Retrospective study using TriNetX.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/safety-of-biologic-therapy-in-psoriasis-patients-with-a-previous-malignancy-retrospective-study-using-trinetx-r609/Background and objectivesEvidence-based recommendations for the treatment of patients with psoriatic disease (PsO) and a prior history of malignancy are limited. This study aimed to compare the incidence of newly diagnosed neoplasms among patients with PsO and a previous malignancy receiving treatment with conventional systemic therapies, apremilast, or biologic agents.

Patients and methods

Retrospective observational study using TriNetX. PsO patients (ICD10:L40) with a previous diagnosis of cancer (ICD10:C00-D49) less than 5 years prior to systemic therapy initiation were selected. Outcomes evaluated included new documentation of neoplasms and all-cause mortality.

Results

Patients under biologic therapy had a significantly lower new neoplasm documentation rate and all-cause mortality compared to classical agents (HR 0.857 and HR 0.705, respectively) and apremilast (HR 0.782 and HR 0.803, respectively) at 3 years follow-up. Only TNFi exhibited a significantly lower new neoplasm rate (HR 0.867, p < 0.0001) compared to classical agents; however, all biologic agents significantly decreased mortality. IL-23i was the only biologic therapy to significantly lower cancer recurrence risk (RR 0.878) compared to TNFi, with no differences in all-cause mortality.

Conclusions

Biologic therapy for PsO may represent a safe treatment option in patients with a history of malignancy, compared with conventional systemic therapies or apremilast. Among biologic agents, IL-23 inhibitors appear to be associated with the most favorable safety profile.

Weiterlesen

]]>609Thu, 23 Apr 2026 06:10:08 +0000Evidence- and consensus-based guideline on lichen sclerosus.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/evidence-and-consensus-based-guideline-on-lichen-sclerosus-r582/Weiterlesen

]]>582Fri, 10 Apr 2026 10:21:31 +0000Evidenz‐ und konsensbasierte (S3) Leitlinie: Lichen sclerosushttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/evidenz%E2%80%90-und-konsensbasierte-s3-leitlinie-lichen-sclerosus-r581/No abstract supplied.

Weiterlesen

]]>581Fri, 10 Apr 2026 10:21:31 +0000The role of inflammatory cell death in type 1 dominant inflammatory skin diseases.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/the-role-of-inflammatory-cell-death-in-type-1-dominant-inflammatory-skin-diseases-r580/Weiterlesen

]]>580Fri, 10 Apr 2026 10:21:31 +0000Should TNF inhibitors be avoided in psoriasis patients with latent tuberculosis?https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/should-tnf-inhibitors-be-avoided-in-psoriasis-patients-with-latent-tuberculosis-r579/No abstract supplied.

Weiterlesen

]]>579Fri, 10 Apr 2026 10:21:31 +0000Palmoplantare Pustulose: Entstehung, Differentialdiagnose und Therapiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/palmoplantare-pustulose-entstehung-differentialdiagnose-und-therapie-r578/No abstract supplied.

Weiterlesen

]]>578Fri, 10 Apr 2026 10:21:31 +0000Palmoplantar pustulosis: pathogenesis, differential diagnosis, and treatment.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/palmoplantar-pustulosis-pathogenesis-differential-diagnosis-and-treatment-r577/Weiterlesen

]]>577Fri, 10 Apr 2026 10:21:31 +0000Ixekizumab optimization in moderate-to-severe plaque psoriasis in real clinical practice: a retrospective multicenter study.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/ixekizumab-optimization-in-moderate-to-severe-plaque-psoriasis-in-real-clinical-practice-a-retrospective-multicenter-study-r539/No abstract supplied.

Weiterlesen

]]>539Mon, 30 Mar 2026 08:02:13 +0000Psychoeducational schema therapy for psoriasis and atopic dermatitis: a randomized controlled pilot crossover trial.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/psychoeducational-schema-therapy-for-psoriasis-and-atopic-dermatitis-a-randomized-controlled-pilot-crossover-trial-r538/Background and objectivesAtopic dermatitis and psoriasis are chronic inflammatory skin diseases often linked to psychological stress. Integrative care models are lacking. This randomized pilot study aimed to develop and test a psychoeducational intervention for dermatology patients.

Patients and methods

Patients with a PHQ-2 score ≥ 3 at an outpatient inflammation center were randomized into an intervention or control group. The intervention group received three standardized educational sessions focusing on maladaptive schemas, coping strategies, psychoeducation, and emotion-focused techniques (e.g. chair-dialogues, imaginary rescripting).

Results

19 patients received the intervention; 13 were in the control group. Post-intervention, significant improvements were observed in dermatological quality of life (DLQI), subjective well-being (WHO-5), and depressive symptoms (PHQ-9, BDI-II). Psychological benefits were largely independent of disease severity (PASI, EASI). Qualitative feedback highlighted usability, learning specific techniques, and a trusting therapeutic relationship.

Conclusions

A brief psychoeducational intervention significantly reduced psychological stress in dermatology outpatients. Further studies are needed to evaluate long-term effects and broader implementation.

Weiterlesen

]]>538Mon, 30 Mar 2026 08:02:13 +0000Simulation der Auswirkungen eines edukativen und digitalen Ansatzes unter Verwendung von Patient‐Journey‐Modellen, um praktische Herausforderungen bei der Behandlung der chronischen spontanen Urtikaria in Deutschland zu bewältigenhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/simulation-der-auswirkungen-eines-edukativen-und-digitalen-ansatzes-unter-verwendung-von-patient%E2%80%90journey%E2%80%90modellen-um-praktische-herausforderungen-bei-der-behandlung-der-chronischen-spontanen-urtikaria-in-deutschland-zu-bew%C3%A4ltigen-r508/No abstract supplied.

Weiterlesen

]]>508Wed, 11 Mar 2026 05:52:25 +0000Lebensqualität bei Patienten mit vernarbender und nicht vernarbender Alopezie: eine explorative Querschnittsstudiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/lebensqualit%C3%A4t-bei-patienten-mit-vernarbender-und-nicht-vernarbender-alopezie-eine-explorative-querschnittsstudie-r507/No abstract supplied.

Weiterlesen

]]>507Wed, 11 Mar 2026 05:52:25 +0000Erfolgreiche Behandlung einer palmoplantaren Pustulose mit Bimekizumab und topischer Photochemotherapie bei gleichzeitig bestehender Hidradenitis suppurativahttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/erfolgreiche-behandlung-einer-palmoplantaren-pustulose-mit-bimekizumab-und-topischer-photochemotherapie-bei-gleichzeitig-bestehender-hidradenitis-suppurativa-r506/No abstract supplied.

Weiterlesen

]]>506Wed, 11 Mar 2026 05:52:25 +0000S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm - part 2: Specific clinical and comorbid situations.https://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-adapted-from-euroguiderm-part-2-specific-clinical-and-comorbid-situations-r460/Weiterlesen

]]>460Sun, 22 Feb 2026 17:23:04 +0000Wohlbefinden bei Patienten mit Vitiligo mit Beteiligung der sichtbaren Hautareale und der Genitalregion in Deutschland– eine fragebogengestützte Pilotstudiehttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/wohlbefinden-bei-patienten-mit-vitiligo-mit-beteiligung-der-sichtbaren-hautareale-und-der-genitalregion-in-deutschland-eine-fragebogengest%C3%BCtzte-pilotstudie-r449/No abstract supplied.

Weiterlesen

]]>449Tue, 10 Feb 2026 08:00:26 +0000Schambezogene Störungen bei Patienten mit atopischer Dermatitis und Psoriasis – eine explorative, Querschnitts‐Interviewstudie zu Prävalenz und Korrelaten körperdysmorpher Störungen und sozialer Angststörungenhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/schambezogene-st%C3%B6rungen-bei-patienten-mit-atopischer-dermatitis-und-psoriasis-eine-explorative-querschnitts%E2%80%90interviewstudie-zu-pr%C3%A4valenz-und-korrelaten-k%C3%B6rperdysmorpher-st%C3%B6rungen-und-sozialer-angstst%C3%B6rungen-r448/No abstract supplied.

Weiterlesen

]]>448Tue, 10 Feb 2026 08:00:26 +0000S3 Guideline for the Treatment of Psoriasis vulgaris, adapted from EuroGuiDerm – part 2: Specific clinical and comorbid situationshttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3-guideline-for-the-treatment-of-psoriasis-vulgaris-adapted-from-euroguiderm-part-2-specific-clinical-and-comorbid-situations-r447/No abstract supplied.

Weiterlesen

]]>447Tue, 10 Feb 2026 08:00:26 +0000S3‐Leitlinie zur Therapie der Psoriasis vulgaris, adaptiert von EuroGuiDerm – Teil 2: Hilfestellungen für besondere klinische Situationen und bei Vorliegen von Komorbiditätenhttps://www.psoriasis-news.de/articles.html/2_psoriasis-im-jddg/s3%E2%80%90leitlinie-zur-therapie-der-psoriasis-vulgaris-adaptiert-von-euroguiderm-teil-2-hilfestellungen-f%C3%BCr-besondere-klinische-situationen-und-bei-vorliegen-von-komorbidit%C3%A4ten-r446/No abstract supplied.

Weiterlesen

]]>446Tue, 10 Feb 2026 08:00:26 +0000